Synthetic mitochondrial protonophores uncouple ATP production, increasing tricarboxylic acid (TCA) cycle activity and fat oxidation to meet energy demands. This approach promotes weight loss and may also enhance glycemic control and lipid metabolism.
MET-097 is a glucagon-like peptide 1 receptor (GLP-1R) agonist developed at Metsera for treating overweight and obesity and is currently in phase II clinical trials.
The main feature of type 1 diabetes is the destruction of pancreatic β cells that produce insulin. Immunotherapy directed at inhibiting immune interactions between cytokines and islet cells and preserving its functioning is key to reverse the progression of the disease.
IBI-3030 from Innovent Biologics Inc. is a novel antibody-peptide conjugate targeting PCSK9 that shows agonism for GLP-1R, GCGR and GIPR, aimed to confer therapeutic benefit against cardiovascular disease.
Amylin is an attractive target in the management of obesity, since it is a peptide hormone co-secreted with insulin in response to food intake, and suppresses appetite and delays gastric emptying. At the American Diabetes Association's Scientific Sessions in Chicago, Structure Therapeutics Inc. presented data regarding the dual amylin receptor and calcitonin receptor agonist ACCG-2671 for obesity treatment.
Abbott Laboratories grabbed attention in early June with its announcement of a partnership with Tandem Diabetes Care Inc. to develop a multianalyte sensor for people with diabetes that would measure ketones as well as glucose.
With a growing number of people wearing continuous glucose monitors and an ever-shrinking number of hospital-based nurses, bringing your own device or using personal CGMs to measure glucose levels during hospitalizations seems like a no-brainer.
Classically, the diagnosis of type 1 diabetes comes after a patient presents with unexplained weight loss, extreme thirst and frequent urination and a lab test reveals off-the-charts blood glucose levels. At the 85th Scientific Sessions of the American Diabetes Association in Chicago, researchers highlighted two options – a blood test and a machine learning model – for diagnosing the disease much earlier in its progression, when damage to the pancreas' beta cells could be slowed.
At the American Diabetes Association 85th Scientific Sessions in Chicago June 20-23, Fractyl Health Inc. presented results from two studies evaluating very different approaches to treating – and possibly curing – type 2 diabetes.
Large-scale human genetic studies have revealed that loss-of-function INHBE variants are associated with a lower abdominal to gluteofemoral fat ratio, improved metabolic profile, and reduced fasting glucose levels.
RSS
